Regulation of α5β1 integrin conformation and function by urokinase receptor binding

被引:111
作者
Wei, Y
Czekay, RP
Robillard, L
Kugler, MC
Zhang, F
Kim, KK
Xiong, JP
Humphries, MJ
Chapman, HA [1 ]
机构
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Pulm & Crit Care Div, San Francisco, CA 94143 USA
[3] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA
[4] Massachusetts Gen Hosp, Struct Biol Program, Charlestown, MA 02129 USA
[5] Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England
关键词
D O I
10.1083/jcb.200404112
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Urokinase-type plasminogen activator receptors (uPARs), up-regulated during tumor progression, associate with beta1 integrins, localizing urokinase to sites of cell attachment. Binding of uPAR to the p-propeller of alpha3beta1 empowers vitronectin adhesion by this integrin. How uPAR modifies other P I integrins remains unknown. Using recombinant proteins, we found uPAR directly binds alpha5beta1 and rather than blocking, renders fibronectin (Fn) binding by alpha5beta1 Arg-Gly-Asp (RGD) resistant. This resulted from RGD-independent binding of alpha5beta1-uPAR to Fn type III repeats 12-15 in addition to type III repeats 9-11 bound by alpha5beta1. Suppression of endogenous uPAR by small interfering RNA in tumor cells promoted weaker, RGD-sensitive Fn adhesion and altered overall alpha5beta1 conformation. A beta1 peptide (res 22,4NLDSPEGGF232) that models near the known alpha-chain uPAR-binding region, or a beta1-chain Ser227Ala point mutation, abrogated effects of uPAR on alpha5beta1. Direct binding and regulation of alpha5beta1 by uPAR implies a modified "bent" integrin conformation can function in an alternative activation state with this and possibly other cis-acting membrane ligands.
引用
收藏
页码:501 / 511
页数:11
相关论文
共 41 条
[1]   Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo [J].
Aguirre-Ghiso, JA ;
Liu, D ;
Mignatti, A ;
Kovalski, K ;
Ossowski, L .
MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (04) :863-879
[2]  
Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684
[3]   Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-β1 integrin complex in colon cancer cells [J].
Ahmed, N ;
Oliva, K ;
Wang, Y ;
Quinn, M ;
Rice, G .
BRITISH JOURNAL OF CANCER, 2003, 89 (02) :374-384
[4]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[5]  
2-Z
[6]   Coming to grips with integrin binding to ligands [J].
Arnaout, MA ;
Goodman, SL ;
Xiong, JP .
CURRENT OPINION IN CELL BIOLOGY, 2002, 14 (05) :641-651
[7]   MONOCLONAL-ANTIBODY 9EG7 DEFINES A NOVEL BETA(1) INTEGRIN EPITOPE INDUCED BY SOLUBLE LIGAND AND MANGANESE, BUT INHIBITED BY CALCIUM [J].
BAZZONI, G ;
SHIH, DT ;
BUCK, CA ;
HEMLER, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (43) :25570-25577
[8]  
Chapman HA, 2001, THROMB HAEMOSTASIS, V86, P124
[9]   Generation of a minimal α5β1 integrin-Fc fragment [J].
Coe, APF ;
Askari, JA ;
Kline, AD ;
Robinson, MK ;
Kirby, H ;
Stephens, PE ;
Humphries, MJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (38) :35854-35866
[10]   Taking cell-matrix adhesions to the third dimension [J].
Cukierman, E ;
Pankov, R ;
Stevens, DR ;
Yamada, KM .
SCIENCE, 2001, 294 (5547) :1708-1712